An Analysis of the PANORAMA 1 Trial

Angela Dispenzieri, MD
Published Online: July 11, 2014
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Clinical Pearls:
  • This was a positive study in terms of progression-free survival. The progression-free survival was about 4 months better in the panobinostat arm.
  • There were significantly more grade 3 toxicities, such as diarrhea, thrombocytopenia and fatigue, in the panobinostat arm.
  • There is no signal in terms of better overall survival.


Related Articles
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma.
Unfortunately, regorafenib has been associated with certain adverse events (AEs), such as hand-foot skin reaction (HFSR) and hypertension.
JTT Articles
Novel Treatment Options for T790M-Mutant Non-Small Cell Lung Cancer
A Long-Awaited Treatment Option for Radioiodine- Refractory DTC
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.